EVALUATION OF COMBINED THERAPY WITH SIMVASTATIN IN PATIENTS WITH ACUTE ISCHEMIC STROKE
The efficacy of simvastatin (40 mg daily) in acute stage of ischemic stroke was evaluated in 12-month comparative randomized study. Patients in the first group (n = 105) received standard antistroke therapy, and patients in the second group (n = 105) also received standard treatment and simvastatin additionally. Combined endpoint (cardiovascular death + recurrent cardiovascular events + necessity of readmission), dynamics of neurological status, endothelial function and renal function were considered. Conclusion: Simvastatin 40 mg/day prescribed along with neuroprotective and antihypertensive treatment in acute stage of ischemic stroke leads to lowering of recurrent cardiovascular events number, positive dynamics of neurological status, regression of endothelial dysfunction, associated with improved renal function.